Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2008-11-26 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations, 5761-2000). The key content states: 'Attached hereto is a report on Form 6-K Resignation of Director (Ben-Zion Weiner)'. This indicates the document itself is an announcement about a specific event (director resignation) and references an attached Form 6-K, which is a report filed with the SEC, often used by foreign private issuers to report material events. Since this is an official regulatory filing announcing a material event (director resignation) that doesn't fit neatly into specific categories like ER, 10-K, or DIV, and it is a formal regulatory submission, the most appropriate general category is Regulatory Filings (RNS). Although it relates to management change (MANG), the structure here is that of a formal, immediate regulatory disclosure, making RNS the best fit as a catch-all for specific regulatory announcements not covered elsewhere.
2008-11-26 English
Board/Management Information 2008
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd., dated November 25, 2008. The key content is the notification of a resignation from the Board of Directors (Ben-Zion Weiner). There is no financial data, no report of financial results, no audit information, no voting results, or other report types. The main subject is a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short (2363 characters), and it is not an announcement of a report publication but a direct notification of a board member resignation. Therefore, the correct classification is MANG with high confidence.
2008-11-25 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is a press release announcing the top-line results of a clinical trial (Phase 2b study) for a pharmaceutical product. It states that the study failed to meet its primary endpoint and includes a CEO comment on next steps. There is no detailed financial data, regulatory form references, or comprehensive report content. The document is short (1191 characters) and serves as an announcement of study results rather than a financial or regulatory filing. It does not fit into categories related to financial reports, governance, or regulatory filings. Given the nature of the announcement, it best fits into the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2008-11-18 Hebrew (modern)
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is very short (1746 characters) and explicitly states that it is an 'Immediate Report' under Israeli regulations. Crucially, the body contains the line: 'Attached hereto is a report on *XTL Biopharmaceuticals Announces Top-line results from the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain Study failed to meet its primary endpoint* *PressReleaseNegativeFinal_isa.pdf*'. This structure—a brief announcement stating that a specific report (in this case, a press release about study results) is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) nor the earnings release (ER), but the notification of the release of specific news/results.
2008-11-18 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces top-line results from a Phase 2b clinical trial, specifically stating the study failed to meet its primary endpoint. The document is relatively short (3364 characters) and primarily serves as an announcement of clinical trial results rather than a detailed financial or management report. It does not contain comprehensive financial statements or detailed analysis typical of annual or interim reports. It also does not fit categories like earnings release or management discussion. Given the nature of the filing (Form 6-K) and the content being an announcement of clinical trial results, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2008-11-18 English
Other Report or Announcement
Regulatory Filings
2008-11-05 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.